TuHURA Biosciences, Inc./NV (HURA): Nasdaq/NYSE listing notice — Kintara Therapeutics gets Nasdaq delisting notice; equity at $731K vs $2.5M requirement

TuHURA Biosciences, Inc./NV

Received Nasdaq notice on Sept 20, 2023 for non-compliance with minimum stockholders' equity requirement of $2.5M; reported equity of $731,000 in FY 2023 10-K.
Company has until Nov 6, 2023 to submit a plan to regain compliance; if accepted, may get up to 180-day extension.
Also does not meet alternative listing standards: market value of listed securities ≥$35M or net income $500K from continuing operations.
Common stock continues trading on Nasdaq under KTRA during compliance process; delisting could reduce liquidity and capital raising ability.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

September 20, 2023, Kintara Therapeutics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, the Company reported stockholders’ equity of $73

View on SEC.gov

1 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-23-049926

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.